Welcome to our dedicated page for Check Cap news (Ticker: CHEK), a resource for investors and traders seeking the latest updates and insights on Check Cap stock.
Check-Cap Ltd. (CHEK) is a clinical-stage innovator in non-invasive screening, developing the C-Scan® ingestible capsule for colorectal cancer detection. This page provides investors and medical professionals with essential updates on the company's advancements in patient-friendly diagnostic technology.
Access authoritative updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated news collection focuses on developments directly impacting Check-Cap's position in preventive healthcare solutions, including technological refinements to its low-dose X-ray imaging system.
Key updates cover FDA communications, trial phase results, and collaborations with healthcare institutions. All content is verified through primary sources to ensure accuracy for investment and research decisions.
Bookmark this page for streamlined access to Check-Cap's evolving role in transforming colorectal screening through preparation-free technology. Monitor critical developments in medical imaging innovation and diagnostic accessibility.
Check-Cap Ltd. (NASDAQ: CHEK, CHEKZ) announced financial results for Q4 and the full year ended December 31, 2022. The company reported a net loss of $3.7 million for Q4 2022, down from $5.5 million in Q4 2021. R&D expenses for the year rose to $14.3 million from $12.3 million, while general and administrative expenses increased to $5.8 million compared to $5.0 million in 2021. The company’s cash position at year-end was $42.1 million, which is projected to fund operations into Q4 2024. However, the initiation of the powered portion of its pivotal U.S. study is postponed as current efficacy results do not meet the required goals.
FAQ
What is the current stock price of Check Cap (CHEK)?
What is the market cap of Check Cap (CHEK)?
